According to Richard J. Willke, PhD, chief science officer of ISPOR, real-world data has some unique advantages over randomized clinical trial findings, especially for health plans looking to make coverage decisions.
According to Richard J. Willke, PhD, chief science officer of ISPOR, real-world data has some unique advantages over randomized clinical trial findings, especially for health plans looking to make coverage decisions.
Transcript (slightly modified)
In what ways can real-world data provide better information for decision making than classical clinical trials?
I would say real-world data should be viewed as complimentary to randomized clinical trial, or RCT, data. RCT data are still the gold standard for determining treatment safety and efficacy of course, but we also know that they’re typically performed in restricted settings and restricted populations, which probably aren’t like the health plan characteristics. So the health plans want to track how the treatment really does in its own population.
One of the first things it looks at is often at adherence, because it’s easy to measure, and then analyze the association with outcomes and probably medical costs. It can also look treatments of populations, 1 treatment versus other comparators, things that were never studied in randomized clinical trials. Now, this has to be done carefully, because the real-world data weren’t randomized, so good methodology is really important. But if it’s done carefully, it can aid health plans in decision making about utilization management, step audits, co-pays, prior authorization: the kind of things that help the health plan optimize one treatment as it fits with other treatments.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More